Mechanism of Action: Estrogen Receptor Antagonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Estrogen Receptor Antagonists
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 11,819,480 | ⤷ Subscribe | ⤷ Subscribe | ||||
Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 11,819,480 | ⤷ Subscribe | ⤷ Subscribe | ||||
Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 10,420,734 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |